$XBI $111.36 -3.53% %
Covid Updates
$GRTS -42.4% Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19 source
Pipeline Updates
$ANNX -23.8% ANNEXON BIOSCIENCES REPORTS PROMISING INTERIM PHASE 2 DATA SHOWING IMPROVEMENT IN CLINICAL MEASURES WITH ANX005 IN HUNTINGTON’S DISEASE FOLLOWING SIX-MONTH TREATMENT source
$JAGX -0.9% Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs source
$SPRO -1.6% Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 source
$AVEO -1.5% AVEO Oncology Highlights Recent Progress and 2022 Outlook source
$UBX +6.3% UNITY BIOTECHNOLOGY PROVIDES PROGRAM UPDATES AND ANTICIPATED MILESTONES FOR 2022 source
$VCNX 0.0% Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety Analysis source
$ASMB -2.0% Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones source
$ALDX -0.7% Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy source
$AYLA -0.6% Ayala Pharmaceuticals Announces Key Business Objectives for 2022 source
$ADVM -7.2% Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy source
$EQ -14.1% Equillium Announces Publication of Data in the Journal of Clinical Investigation Highlighting the Importance of the CD6-ALCAM Pathway in the Pathogenesis of Lupus Nephritis source
$EQ -14.1% Equillium Announces Data from Phase 1b EQUIP Study in Patients with Uncontrolled Asthma source
$RLAY -2.5% Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008 source
$PRQR +3.8% ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen source
$AVRO -36.6% AVROBIO Reprioritizes Pipeline Programs source
$CNCE -0.6% CONCERT PHARMACEUTICALS COMPLETES ENROLLMENT IN THRIVE-AA2 PHASE 3 CLINICAL TRIAL EVALUATING CTP-543 FOR ALOPECIA AREATA source
$GNCA -3.3% Genocea Biosciences Provides Corporate Update source
$CGEM +1.6% FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer source
$EVLO -3.5% Evelo Biosciences Announces Key 2022 Strategic Priorities and Upcoming Catalysts source
$CMPS -5.9% COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology source
$PSTV +17.4% PLUS THERAPEUTICS ANNOUNCES TWO SIGNIFICANT MILESTONES TOWARD CGMP MANUFACTURE OF ITS LEAD INVESTIGATIONAL RADIOTHERAPEUTIC source
Business Updates
$
Posted by JM
Komentarze